ArticleJournal of pharmaceutical health care and sciences2026
Incidence and clinical characteristics of zolbetuximab-induced nausea and vomiting in CLDN18.2-positive unresectable advanced or recurrent gastric cancer: a retrospective study.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma.Medical oncology (Northwood, London, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundZolbetuximab for CLDN18.2-positive advanced gastric cancer frequently causes chemotherapy-induced nausea and vomiting (CINV), particularly during the first infusion. Single-center studies in Japan have reported standardized infusion protocols and antiemetic strategies; however, these uniform approaches do not allow evaluation of how differences in infusion rate settings, antiemetic combinations, or patient backgrounds influence CINV. Using real-world data from multiple institutions with various clinical practices, the aim of this study was to clarify factors associated with CINV during the first zolbetuximab infusion, focusing on infusion rate, antiemetic use, and patient characteristics.
methodsThis multicenter retrospective study included patients with CLDN18.2-positive unresectable or recurrent gastric cancer who received zolbetuximab between June 2024 and April 2025. Clinical characteristics, gastrectomy status, infusion parameters, antiemetic use, and CINV events during the first infusion were extracted from electronic medical records. CINV severity was assessed using CTCAE or patient-reported scales (NRS and Faces Scale), depending on institutional practice. Accordingly, CTCAE Grade ≥ 2, NRS ≥ 3, or Faces Scale ≥ 6 were defined as moderate-or-greater nausea. Patient backgrounds were summarized using descriptive statistics. Associations between CINV and age group, sex, gastrectomy status, antiemetic combinations, and infusion-rate categories were evaluated with exploratory analyses using Fisher’s exact or χ2 tests.
resultsForty-four patients were analyzed. CINV during the first zolbetuximab infusion was more frequent in patients without gastrectomy (38.7%) than in those with gastrectomy (7.7%). Younger age was associated with increased risk, whereas sex differences were minimal. Olanzapine use reduced the incidence of moderate-or-greater nausea or any-grade vomiting (18.2% vs 32.4%). CINV typically occurred when infusion rates reached approximately 200–250 mg/h, suggesting an increased risk when rates exceeded approximately 150 mg/h. Combined risk analysis showed that gastrectomy status had a stronger influence on CINV than age or sex, and olanzapine further reduced risk among non-gastrectomized patients.
conclusionInfusion-phase CINV during the first zolbetuximab infusion was associated with both patient-related and administration-related factors in real-world practice. Quantitative evaluation of infusion-rate ranges and the influence of gastric mucosal status suggest that nausea severity may be partially modifiable through optimized infusion management and risk-adapted antiemetic strategies. These exploratory findings warrant prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.